Q1 2019 Medivir AB Earnings Call Transcript
Ladies and gentlemen, welcome to the Medivir AB Q1 Report 2019. (Operator Instructions) Today, I am pleased to present, Uli Hacksell, CEO. Please begin.
()- -
Thank you, and good afternoon.
We meet today Lotta Ferm, who is our Interim CFO, and I have Linda Basse, who is our Chief Medical Officer, who will be able to answer any medical questions as well.
Let me move to Slide #2, and I encourage you to read that because it contains information about risk factors, et cetera, that are important to understand.
Let's move to the next Slide #3. We have had an exciting start of 2019 with our zoomed in focus on oncology, on clinical development and on business development. When it comes to the clinical development, we have 2 ongoing studies, which are very exciting for us. A study with a combination of birinapant and Keytruda where we have already recruited 14 patients in our colorectal cancer study and where we expect to have an interim
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
